

Cure Parkinson's

Donations acceptance policy

1. Purpose

1.1. This document sets out the CURE PARKINSON'S policy for the acceptance of donations. It is intended for prospective donors and their advisers, providing assurance that all donors are treated equitably.

1.2 CURE PARKINSON'S actively encourages philanthropic support, in line with its charitable status, and views increasing such support as a key element in being able to fulfil its objectives.

2. Context

2.1. The Cure Parkinson's Trust is a registered charity in England and Wales (1111816) and Scotland (SCO44368) and a company limited by guarantee - company number 5539974.

2.2 The charity is governed by a volunteer trustee board. In principle, trustees of a charity are expected to accept money given to that charity for purposes consistent with the charity objects, but the trustees have discretion to consider other factors relevant to the charity's powers and obligations.

2.3 In addition, the UK Bribery Act 2010 requires CURE PARKINSON'S to ensure that the receipt of a donation is not related to some inappropriate advantage that be afforded to the donor, such as the opportunity to take part in a clinical trial. Other relevant legislation includes the Proceeds of Crime Act 2002, the Terrorism Act 2000 and the Money Laundering Regulations 2007 under which it is an offence to receive, retain or convert money or property known or reasonably suspected to be the product of criminal activity.

3. Definitions and scope

3.1. This policy applies to all donations received by CURE PARKINSON'S. A "donation" (as used here) is a voluntary transfer of money or property by an individual or organisation made with philanthropic intent for the benefit of CURE PARKINSON'S. Donations can include (without limitations) gifts of money, grants, legacies, sponsorship and gifts of other property.

3.2. CURE PARKINSON'S actively seeks and can accept donations from the following sources in accordance with this policy:

- Individuals in the UK and overseas
- Charitable trusts and foundations in the UK and overseas
- Companies in the UK and overseas
- Legacy bequests
- UK or overseas governments or their agencies and foundations

4. Acceptance Principles

4.1 When deciding whether to accept any donation, CURE PARKINSON'S is guided by its objects, powers and obligations outlined in its Memorandum and Articles of Association, the Code of Fundraising Practice implemented by the Fundraising Regulator and The Institute of Fundraising, and all relevant legislation and regulations.

4.2 CURE PARKINSON'S will not accept donations where such donations have:

- been illegally or unethically obtained , or if
- acceptance of the donation may damage the reputation of CURE PARKINSON'S

4.3 CURE PARKINSON'S will not accept donations which compromise the independence of CURE PARKINSON'S. Examples include, but are not limited to, the provision of donations:

- with an intent to influence the research strategy and funding of CURE PARKINSON'S;
- which intend to affect or influence trial or other research participation;
- which give rise to an unacceptable conflict of interests; or
- that are conditional upon any particular person being made a patron or other position within CURE PARKINSON'S.

4.4 CURE PARKINSON'S will not accept donations which are counter to CURE PARKINSON'S interests. Examples include, but are not limited to, donations that:

- Do not further, or are in conflict with, CURE PARKINSON'S mission and/or values;
- Are too difficult or expensive to administer or could create unacceptable liability or future expense (in each case in the absolute discretion of the CEO and/or trustees of CURE PARKINSON'S);

4.5 CURE PARKINSON'S will not accept donations where it has reason to believe that the donor may be experiencing vulnerable circumstances and accepting the donation would be ethically wrong and/or unreasonably harmful to the donor (in each case in the absolute discretion of the CEO and/or trustees of CURE PARKINSON'S).

4.5.1 CURE PARKINSON'S does not identify vulnerable adults based on disability or age or any other social indicator. CURE PARKINSON'S deals with each donor on a case-by-case basis. Each fundraiser, when interacting with a potential donor, shall consider the relevant context to determine whether or not the donor should be considered vulnerable or the donation otherwise wrong or harmful, and (if concerned) seek guidance from the CURE PARKINSON'S fundraising manager or (if necessary) CEO.

5. Major proposals, ethics and naming convention

5.1 Major Funding Proposals

5.1.1 Major funding proposals will be subject to approval by the CEO prior to the proposal being accepted.

5.2 Ethical Screening and Independence

5.2.1 With respect to donors that pose potentially high ethical or reputational risks, approval from the CEO must be obtained prior to a proposal for a donation being accepted.

5.3 Donors shall not, as a result of any donation influence any appointment by CURE PARKINSON'S to any position within CURE PARKINSON'S (as an executive or trustee whether paid or unpaid), or within any CURE PARKINSON'S- related research projects.

5.4 Naming Recognition

5.4.1 The “naming” (e.g. requiring a specific name or brand to be associated with a particular event or activity) of proposed donations will be subject to levels of approval as follows, in each case before the funding announcement becomes public:

a) The naming of any academic position as part of a donor agreement will be subject to review and approval from CURE PARKINSON'S trustee board.

b) The naming of a scholarship, award, prize or bursary as part of a donor agreement will be subject to review and approval by the CEO.

5.4.2 Any approved “naming” may be withdrawn by CURE PARKINSON'S where subsequent concerns arise regarding the source of the funding or the individual or organisation named.

6. Approval of “acceptances” above

If it appears that a proposed donation may violate one of the principles at section 4 or section 5 of this policy, the member of staff soliciting or negotiating the donation on behalf of CURE PARKINSON'S must bring it to the attention of the CEO (and/or the chair of the CURE PARKINSON'S trustees), as soon as possible, to determine further action.

7. Legacies

CURE PARKINSON'S welcomes notification by donors that they have included CURE PARKINSON'S in their Wills or legacy planning. CURE PARKINSON'S records this information confidentially in its database, and may (in CURE PARKINSON'S discretion) honour any donor's generous intentions with an invitation to events as appropriate.

8. Gift Restrictions

8.1 In appreciation of any substantial philanthropic support, CURE PARKINSON'S may accept “restricted donations”, being donations which are made with either:

- (1) a preference; or
- (2) a strict limitation to a particular project or scientific programme.

8.2.1 However, any approved restrictions must fit within the mission of the CURE PARKINSON'S.

8.2.2 Restricted donations are subject to the approval of the CEO.

8.3 CURE PARKINSON'S policy is to favour unrestricted donations over “restricted donations” and will typically seek to avoid restrictions. However:

- (1) if a donor insists that a donation is a “restricted donation”, this will typically be acceptable; and
- (2) in some cases, CURE PARKINSON'S will propose a particular project or programme, in which case such donations shall be acceptable (for example, where donations are sought by way of sponsorship for a particular event or project).

9. Gift processing and acknowledgement

9.1 All donations to CURE PARKINSON'S must be processed and recorded confidentially on CURE PARKINSON'S database to ensure compliance with this policy.

9.2 CURE PARKINSON'S may accept the following types of asset as a donation:

- Cash
- Securities - stocks and bonds (by prior agreement with the CEO)
- Property and other real estate (by prior agreement with the CEO)
- Personal property which may be auctioned or otherwise sold (if significant, with prior agreement with the CEO)
- Personal property which is not (necessarily) to be sold (see below).

9.3 CURE PARKINSON'S may accept donations of personal property which is not (necessarily) to be sold, including intellectual property, by prior agreement of the CEO and, if of strategic or structural significance, the trustees. Examples may include: major works of art, software licences and large-scale computer hardware.

9.4 CURE PARKINSON'S accepts donations provided either (1) with donor identity or (2) anonymously (for example, via JustGiving, the CURE PARKINSON'S website, post or via trusts or representatives). However, *unverified or suspicious* anonymous donations over £25,000 need to be reported to the Charity Commission as a "serious incident", so in every case where an anonymous donation of £10,000 is received, the CEO, Director of Fundraising & Marketing or Director of Finance should be consulted for guidance.

9.5 For any donations provided to CURE PARKINSON'S with donor identity, CURE PARKINSON'S will also honour any donor's wish to remain anonymous externally, but full details of identity will be recorded on the CURE PARKINSON'S database.

9.6 All donors and legacy pledgers will receive appropriate acknowledgement and recognition, as well as assurance (if relevant) that their gift is used for the purposes designated (in addition, see paragraph 10 below regarding larger gifts).

10. Larger donation acknowledgements

10.1 In the case of larger gifts (e.g. over £5,000), CURE PARKINSON'S must consider whether its acknowledgement and recognition should go into greater detail than for smaller gifts, and be followed up with more information and updates, as may be proportionate to the size of gift and the wishes of the donor.

11. Legal or financial advice

CURE PARKINSON'S does not provide legal, financial advice or any financial planning services. Prospective donors should seek the assistance of their own legal and/or financial advisors (if needed) in any significant matters relating to donations, tax and/or estate planning. If CURE PARKINSON'S is asked to assist in these areas, it shall decline.

12. Roles and Responsibilities

12.1 The CURE PARKINSON'S trustees (advised as appropriate by the CURE PARKINSON'S Governance & Risk Committee of trustees) have overall responsibility for this policy, including the specific responsibilities set out herein.

12.2 Subject to clause 12.1 above, the CEO is responsible for implementing and enforcing this policy, including the specific responsibilities set out herein.